Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Petrelli

Showing results (291-300 of 304) with videos related to

Pageof 31
Sort By:
Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.
Cancers|September 28, 2023
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer PatientsPatricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino studyAlessandra Raimondi, Massimo Di Maio, Federica Morano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2021
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino studyAlessandra Raimondi, Salvatore Corallo, Sara Lonardi, et al.
JAMA Oncology|July 4, 2019
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialFilippo Pietrantonio, Federica Morano, Salvatore Corallo, et al.
Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
Pageof 31

Showing results (291-300 of 304) with videos related to

Sort By:
Pageof 31
Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.
Cancers|September 28, 2023
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer PatientsPatricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino studyAlessandra Raimondi, Massimo Di Maio, Federica Morano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2021
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino studyAlessandra Raimondi, Salvatore Corallo, Sara Lonardi, et al.
JAMA Oncology|July 4, 2019
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialFilippo Pietrantonio, Federica Morano, Salvatore Corallo, et al.
Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
Pageof 31